FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199048125> ?p ?o ?g. }

• W3199048125 abstract "Background: Vaccines against COVID-19 are a powerful tool to control the current SARS-CoV-2 pandemic. A thorough description of their immunogenicity among people living with HIV (PLWHIV) is necessary. We aimed to assess the immunogenicity of the mRNA-1273 vaccine among PLWHIV.Methods: In this prospective cohort, adult PLWHIV outpatients were enrolled during the Italian vaccination campaign. Enrolment was allowed irrespective of ongoing combination antiretroviral therapy (ART), plasma HIV viral load and CD4+ T cell count. A two-dose regimen of mRNA-1273, with administrations performed 28 days apart, was employed. The primary outcomes were anti-spike (anti-S) antibody titres and neutralising antibody activity, assessed 28 days after completing the vaccination schedule, compared with individuals not affected by HIV (referred as healthy-donors, HDs).  Findings: CD4+ T cell count groups and anti-nucleocapside (anti-N) positive serology were the only variables associated with anti-spike (anti-S) antibody titres (expressed as U/mL) and neutralising antibody activity. Anti-S antibodies were higher in COVID-19-experienced PLWHIV (median 12500 U/mL IQR [5704-12500]) than in COVID-19-naive PLWHIV (median 2437 U/mL IQR [1485-4526]) but did not differ from those observed in COVID-19-experienced HDs (median 1077 U/mL IQR [702-7551]). Neutralising antibody activity in sera was higher in COVID-19-experienced PLWHIV (median 10888 IQR [2478-14416]) compared to COVID-19-naive PLWHIV (median 1192 IQR [742-2421]) but was comparable to those observed in COVID-19-experienced HDs (median 20959 U/mL IQR [10060-31857]). When stratified according to CD4+ T cell count ( 500 cells/μL), anti-S antibody titres (median 2173 U/mL [IQR 897-4109], 5763 IU/mL [IQR 4801-12500], 2449 U/mL [IQR 1524-5704]) were not lower to those observed among HDs (median 1425 U/mL [IQR 599-6131]). In addition, neutralising antibody activity, stratified according to the CD4+ T cell count (median 1314 [IQR 606-2477], 3329 IU/mL [IQR 1905-10508], 1227 U/mL [IQR 761-3032]), was similar to those displayed by HDs (median 2112 U/mL [IQR 719-8889]).Interpretation: Inoculation with mRNA-1273 vaccine given 4 weeks apart produced adequate immune responses in PLWHIV, who are well controlled on ART, irrespective of CD4+ T cell count and equivalent to individuals without HIV infection, supporting vaccination in PLWHIV.Funding: This study was partially supported by Italian Ministry of Health Ricerca Corrente 2021 and Grant Ricerca Finalizzata GR 2018-12365699, by Intesa San Paolo COVID-19 emergency 2020 funds, and by Fondazione Cariplo (INNATE-CoV).Declaration of Interest: All other authors declare no competing interests.Ethical Approval: The study protocol (286_2021) was approved by the INMI “Lazzaro Spallanzani” Ethics Committee (Roma, Italy)," @default.
• W3199048125 created "2021-09-27" @default.
• W3199048125 creator A5001887891 @default.
• W3199048125 creator A5010393338 @default.
• W3199048125 creator A5011559605 @default.
• W3199048125 creator A5015831825 @default.
• W3199048125 creator A5016860319 @default.
• W3199048125 creator A5020839004 @default.
• W3199048125 creator A5024285334 @default.
• W3199048125 creator A5024712080 @default.
• W3199048125 creator A5029464276 @default.
• W3199048125 creator A5036094763 @default.
• W3199048125 creator A5042447844 @default.
• W3199048125 creator A5044798578 @default.
• W3199048125 creator A5046409179 @default.
• W3199048125 creator A5053530719 @default.
• W3199048125 creator A5056275752 @default.
• W3199048125 creator A5062499426 @default.
• W3199048125 creator A5064631193 @default.
• W3199048125 creator A5071587401 @default.
• W3199048125 creator A5071739282 @default.
• W3199048125 creator A5072777442 @default.
• W3199048125 creator A5086168854 @default.
• W3199048125 date "2021-01-01" @default.
• W3199048125 modified "2023-09-27" @default.
• W3199048125 title "Anti-Spike Antibodies and Neutralising Antibody Activity in People Living with HIV Vaccinated with COVID-19 mRNA-1273 Vaccine: A Prospective Cohort Study" @default.
• W3199048125 cites W1969952390 @default.
• W3199048125 cites W1991698426 @default.
• W3199048125 cites W2059790979 @default.
• W3199048125 cites W2108018524 @default.
• W3199048125 cites W2114288236 @default.
• W3199048125 cites W2118425309 @default.
• W3199048125 cites W2120079411 @default.
• W3199048125 cites W2127133427 @default.
• W3199048125 cites W2167706899 @default.
• W3199048125 cites W2333776588 @default.
• W3199048125 cites W3008394341 @default.
• W3199048125 cites W3111255098 @default.
• W3199048125 cites W3139251053 @default.
• W3199048125 cites W3158010736 @default.
• W3199048125 cites W3188350838 @default.
• W3199048125 cites W4205483821 @default.
• W3199048125 doi "https://doi.org/10.2139/ssrn.3918861" @default.
• W3199048125 hasPublicationYear "2021" @default.
• W3199048125 type Work @default.
• W3199048125 sameAs 3199048125 @default.
• W3199048125 citedByCount "0" @default.
• W3199048125 crossrefType "journal-article" @default.
• W3199048125 hasAuthorship W3199048125A5001887891 @default.
• W3199048125 hasAuthorship W3199048125A5010393338 @default.
• W3199048125 hasAuthorship W3199048125A5011559605 @default.
• W3199048125 hasAuthorship W3199048125A5015831825 @default.
• W3199048125 hasAuthorship W3199048125A5016860319 @default.
• W3199048125 hasAuthorship W3199048125A5020839004 @default.
• W3199048125 hasAuthorship W3199048125A5024285334 @default.
• W3199048125 hasAuthorship W3199048125A5024712080 @default.
• W3199048125 hasAuthorship W3199048125A5029464276 @default.
• W3199048125 hasAuthorship W3199048125A5036094763 @default.
• W3199048125 hasAuthorship W3199048125A5042447844 @default.
• W3199048125 hasAuthorship W3199048125A5044798578 @default.
• W3199048125 hasAuthorship W3199048125A5046409179 @default.
• W3199048125 hasAuthorship W3199048125A5053530719 @default.
• W3199048125 hasAuthorship W3199048125A5056275752 @default.
• W3199048125 hasAuthorship W3199048125A5062499426 @default.
• W3199048125 hasAuthorship W3199048125A5064631193 @default.
• W3199048125 hasAuthorship W3199048125A5071587401 @default.
• W3199048125 hasAuthorship W3199048125A5071739282 @default.
• W3199048125 hasAuthorship W3199048125A5072777442 @default.
• W3199048125 hasAuthorship W3199048125A5086168854 @default.
• W3199048125 hasConcept C126322002 @default.
• W3199048125 hasConcept C159047783 @default.
• W3199048125 hasConcept C159654299 @default.
• W3199048125 hasConcept C203014093 @default.
• W3199048125 hasConcept C2779134260 @default.
• W3199048125 hasConcept C2909509916 @default.
• W3199048125 hasConcept C3007834351 @default.
• W3199048125 hasConcept C3008058167 @default.
• W3199048125 hasConcept C3013748606 @default.
• W3199048125 hasConcept C524204448 @default.
• W3199048125 hasConcept C71924100 @default.
• W3199048125 hasConcept C72563966 @default.
• W3199048125 hasConceptScore W3199048125C126322002 @default.
• W3199048125 hasConceptScore W3199048125C159047783 @default.
• W3199048125 hasConceptScore W3199048125C159654299 @default.
• W3199048125 hasConceptScore W3199048125C203014093 @default.
• W3199048125 hasConceptScore W3199048125C2779134260 @default.
• W3199048125 hasConceptScore W3199048125C2909509916 @default.
• W3199048125 hasConceptScore W3199048125C3007834351 @default.
• W3199048125 hasConceptScore W3199048125C3008058167 @default.
• W3199048125 hasConceptScore W3199048125C3013748606 @default.
• W3199048125 hasConceptScore W3199048125C524204448 @default.
• W3199048125 hasConceptScore W3199048125C71924100 @default.
• W3199048125 hasConceptScore W3199048125C72563966 @default.
• W3199048125 hasLocation W31990481251 @default.
• W3199048125 hasOpenAccess W3199048125 @default.
• W3199048125 hasPrimaryLocation W31990481251 @default.
• W3199048125 hasRelatedWork W2603773853 @default.
• W3199048125 hasRelatedWork W3034816694 @default.
• W3199048125 hasRelatedWork W3036305013 @default.
• W3199048125 hasRelatedWork W3127693599 @default.

• next